Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.39 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PPIA | P62937 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452137 | 1.00 | ADRB2 (0.44) | ADRB2NR3C1ADRB3PDE4APDE4B | |
| SCHEMBL13842583 | 0.90 | ADRB2 (0.45) | ADRB2ADRB3PDE4APDE4BPDE4C | |
| SCHEMBL5037668 | 0.90 | ADRB2 (0.47) | ADRB2ADRB3PDE4APDE4BPDE4C | |
| SCHEMBL2962080 | 0.89 | ADRB2 (0.48) | ADRB2ADRB3PDE4APDE4BPDE4C | |
| SCHEMBL2962085 | 0.89 | ADRB2 (0.48) | ADRB2ADRB3PDE4APDE4BPDE4C | |
| SCHEMBL5037003 | 0.88 | ADRB2 (0.44) | ADRB2ADRB3TRPV1 | |
| SCHEMBL5037004 | 0.88 | ADRB2 (0.44) | ADRB2ADRB3TRPV1 | |
| SCHEMBL12305648 | 0.88 | ADRB2 (0.44) | ADRB2NR3C1ADRB3PDE4APDE4B | |
| SCHEMBL2452521 | 0.88 | ADRB2 (0.54) | ADRB2ADRB3 | |
| SCHEMBL2452518 | 0.88 | ADRB2 (0.54) | ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013019-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | BROWN ALAN DANIEL | 2010-10-28 | — | — | US | disclosed |
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767715-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | BROWN ALAN DANIEL | 2009-08-06 | — | — | US | disclosed |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | BROWN ALAN DANIEL | 2009-08-06 | — | — | US | disclosed |
| US-7528170-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528170-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | BROWN ALAN DANIEL | 2008-10-30 | — | — | US | disclosed |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | BROWN ALAN DANIEL | 2008-10-30 | — | — | US | disclosed |
| EP-1708991-B1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244766-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1708991-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005080313-A9 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005080313-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273758-A1 | Sulfonamide Derivatives For The Treatment Of Diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885NR3C1 1845/4885ADRB3 2520/4885 |
| US-20090197912-A1 | Sulfonamide Derivatives for the Treatment of Diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885NR3C1 1845/4885ADRB3 2520/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | ADRB2 119/4885NR3C1 144/4885ADRB3 107/4885 |
| US-20080267970-A1 | Sulfonamide Derivatives For The Treatment of Diseases | SULT2A1, STS, SULT1A1 | ADRB2 2148/4885NR3C1 1845/4885ADRB3 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.